March 11th 2023
Catch up on the latest CMEs in Psychiatric Times.
February 28th 2023
February 25th 2023
Pharmacological Management of Treatment-Resistant Anorexia NervosaJanuary 26th 2022
Only 13% to 50% of AN patients are considered recovered 1 to 2 years posttreatment, and 20% to 30% go on to develop a chronic and unremitting course of AN. How can we improve these outcomes?
Higher Levels of Care for Eating Disorders: A Practical GuideOctober 31st 2019
Eating disorders (ED) are associated with significant comorbid psychopathology and the most extensive medical complications of any psychiatric disorder.
Understanding and Treating Avoidant Restrictive Food Intake Disorder in Children and AdolescentsOctober 31st 2019
Avoidant restrictive food intake disorder, or ARFID, is a newly introduced eating disorder in DSM-5. Given that the disorder was introduced in 2013, it remains unclear how prevalent ARFID is in the general population.
How Anxiety and Habits Contribute to Anorexia NervosaSeptember 30th 2019
Anorexia nervosa (AN) is a severe and debilitating illness with one of the highest mortality rates of any psychiatric disorder. The illness course is often long, recovery is slow, and the rates of full recovery are low.
Interoception in Eating Disorders: A Clinical PrimerSeptember 30th 2019
More than two-thirds of patients with eating disorders also have comorbid mood and anxiety disorders. This article considers how a transdiagnostic process called interoception may help to advance our understanding and treatment of eating disorders.
Closing the Research-Practice Gap in Eating DisordersSeptember 30th 2019
Eating disorders (EDs) are associated with high medical and psychiatric comorbidity, poor quality of life, and high mortality, and mortality from anorexia nervosa (AN) is the highest of all mental disorders. Fortunately, there are a number of evidence-based psychological treatment approaches for EDs.
Treatment-Resistant Bulimia Nervosa: Clinical Implications and Future DirectionsNovember 27th 2017
Dialectical behavior therapy may be particularly effective in mitigating biologically-driven vulnerabilities, and zonisamide and lamotrigine may play a role.